CRC 11090: (ARCHER 1042 Study) A Phase 2, Multi-Cohort Study To Evaluate The Impact Of Prophylactic Intervention On Dermatologic And Gastrointestinal Adverse Events And Patient Reported Outcomes In Patients Treated With Dacomitinib (PF-00299804)
- Type of Study
- Cancer (Oncology) - Lung
- Location
- Swedish Cancer Institute
- Short Description
Purpose: To assess the impact of prophylactic treatment on the incidence of adverse events in advanced refractory NSCLC patients treated with PF-00299804 daily as a single agent. To assess the impact of an interrupted PF-00299804 dosing schedule in Cycle 1 on the incidence of adverse events in first-line advanced NSCLC patients with an EGFR mutation (HER-1 mutation, HER-2 mutation or HER-2 amplification).
- Status
- Open to Enrollment
- Principal Investigator
- Howard (Jack) West, M.D.
- Eligibility Notes
- Advanced Non-Small Cell Lung Cancer (NSCLC)
- Prior systemic treatment which includes one standard chemotherapy and failed (refractory) for advanced or metastatic NSCLC
- Evidence of disease but measurable disease is not mandatory
- Eastern Cooperative Oncology Group (ECOG) Performance status 0-2, estimated creatinine clearance ≥15 mL/min
- No prior treatment with an EGFR-targeted or HER-targeted agent.
- No chemotherapy, radiotherapy, biological or investigational agents within 2 weeks of baseline disease assessments.
- No patients with known diffuse interstitial lung disease
- More Info Link
- Additional information about the study summary and eligibility criteria may be viewed on the U.S. National Institutes of Health (NIH) website.
- Phone
- (206) 215-3086
